Ryutaro Shimazaki

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

Yoshimasa Kosaka, Yoshiaki Rai, Norikazu Masuda et al. · Supportive Care in Cancer · 2015 · 101 citations · Full text

Medicine, Oncology, Pharmacology +17

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Masafumi Fukagawa, Ryutaro Shimazaki, Tadao Akizawa · Kidney International · 2018 · 89 citations

Medicine, Pharmacology, Pharmacotherapy +12

Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate

Kunihiro Matsushita, Jingsha Chen, Yingying Sang et al. · Kidney International · 2016 · 61 citations

Medicine, Nephrology, Renal Pathophysiology +12

Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses

Hiroshi Ishii, Takushi Nomura, Hiroyuki Yamamoto et al. · Cell Reports Medicine · 2022 · 60 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial

Norikazu Masuda, Yutaka Tokuda, Seigo Nakamura et al. · Supportive Care in Cancer · 2015 · 45 citations · Full text

Pharmacy, Oncology, Pharmacology +13